Peptipedia
Anti-AgingPreclinicalAnimal Studies

Humanin

Also known as HN, HNG (S14G-humanin)

A mitochondria-derived peptide discovered for its neuroprotective effects against Alzheimer's-related toxicity.

Preclinical - Extensive animal research
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

5-10 mg weekly divided into 2-3 injections

Frequency

2-3x weekly

Duration

Variable

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 5-10 mg weekly divided into 2-3 injections via Subcutaneous injection, 2-3x weekly. Dose range: 5-10 mg weekly. Duration: Variable.

Timing & Administration

Administer via Subcutaneous injection. Frequency: 2-3x weekly.

Mechanism of Action

Acts through STAT3 signaling, IGFBP-3 binding, and FPRL1 receptor activation. Protects neurons from apoptosis, improves insulin sensitivity, exhibits anti-inflammatory properties.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical - Extensive animal research.

Side Effects & Safety

Important Warnings

  • No human clinical trial data available
  • Potential pro-tumoral effects.
Mild injection site reactions
potential pro-tumoral effects
may affect glucose metabolism

References

No references available.

Related Peptides

Browse all →
DSIPAnti-Aging

A peptide studied for its ability to promote deep sleep and modulate stress hormones.

View profile
NAD+ PrecursorsAnti-Aging

While not peptides, NAD+ precursors are frequently discussed alongside peptides in longevity circles. They boost cellular NAD+ levels, supporting energy metabolism and sirtuin activity.

View profile
SS-31Anti-Aging

A mitochondria-targeted peptide that improves cellular energy production. FDA approved for Barth syndrome in September 2025.

View profile